Despite matching the basic clinical characteristics between the control and CBF groups, our findings indicate that the CBF‐AML group exhibited a reduction in DFS and an increase in NRM when compared to non‐CBF‐AML patients. This evidence concerns the gene CEBPZ and acute myeloid leukemia.